The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 11, 2013, Pages

  Ferder, Marcelo ^a   Inserra, Felipe ^b   Manucha, Walter ^c   Ferder, León ^d  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD AUSTRAL   (Argentina)

^c UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^d PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Angiotensin receptor blocker; Cardiovascular disease; Mitochondria; Oxidative stress; Vitamin D receptor

Indexed keywords

25 HYDROXYVITAMIN D; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERGOCALCIFEROL; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELANIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PARICALCITOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIRTUIN 3; SUPEROXIDE; VITAMIN D; VITAMIN D RECEPTOR;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BONE METABOLISM; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DNA SEQUENCE; ESSENTIAL HYPERTENSION; FOREARM BLOOD FLOW; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; KIDNEY PERFUSION; METABOLIC SYNDROME X; MITOCHONDRION; NEOPLASM; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PANDEMIC; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SYSTOLIC BLOOD PRESSURE; TH1 TH2 BALANCE; ULTRAVIOLET B RADIATION; VASCULAR SMOOTH MUSCLE; VASCULITIS; VITAMIN D DEFICIENCY;

ANGIOTENSIN RECEPTOR BLOCKER; CARDIOVASCULAR DISEASE; MITOCHONDRIA; OXIDATIVE STRESS; VITAMIN D RECEPTOR;

ANIMALS; HUMANS; INFLAMMATION; PANDEMICS; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D DEFICIENCY; WORLD HEALTH;

EID: 84875509813     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00403.2011     Document Type: Review

References (182)

1. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O'Rourke B, Walston JD. Identification and characterization of a functional mito-chondrial angiotensin system. Proc Natl Acad Sci USA 108: 14849-14854, 2011.
2. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens 13: 31S-38S, 2000.
3. Anderson JW, Gowri MS, Turner J, Nichols L, Diwadkar VA, Chow CK, Oeltgen PR. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr 18: 451-461, 1999.
4. Andersson TL, Matz J, Ferns GA, Anggard EE. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis 111: 39-45, 1994.
5. Aquila S, Guido C, Middea E, Perrotta I, Bruno R, Pellegrino M, Ando S. Human male gamete endocrinology: 1α, 25-dihydroxyvitamin D3 (1, 25(OH)2D3) regulates different aspects of human sperm biology and metabolism. Reprod Biol Endocrinol 7: 140, 2009.
6. Asayama K, Uchida N, Nakane T, Hayashibe H, Dobashi K, Amemiya S, Kato K, Nakazawa S. Antioxidants in the serum of children with insulin-dependent diabetes mellitus. Free Radic Biol Med 15: 597-602, 1993.
7. Bader M, Ganten D. Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med 78: 130-139, 2000.
8. Ballermann BJ, Zeidel ML, Gunning ME, Brenner BM. Vasoactive peptides and the kidney. In: The Kidney, edited by Brenner BM, Rector FC. Philadelphia, PA: Saunders, 1991, p. 510-583.
9. +T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 195: 603-616, 2002.
10. Barsony J, Renyi I, McKoy W. Subcellular distribution of normal and mutant vitamin D receptors in living cells. Studies with a novel fluores-cent ligand. J Biol Chem 272: 5774-5782, 1997.
11. Baylis C, Engels K, Hymel A, Navar LG. Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat. Mech Ageing Dev 97: 163-172, 1997.
12. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the ANG II type 1 receptor promotes longevity in mice. J Clin Invest 119: 524-530, 2009.
13. Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Presse Med 31: 1714-1720, 2002.
14. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84: 18-28, 2006.
15. +T cells to enhance the development of Th2 cells. J Immunol 167: 4974-4980, 2001.
16. Bullock GR, Steyaert I, Bilbe G, Carey RM, Kips J, De Paepe B, Pauwels R, Praet M, Siragy HM, de Gasparo M. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 115: 117-124, 2001.
17. Burgess ED, Hawkins RG, Watanabe M. Interaction of 1, 25-dihy-droxyvitamin D and plasma renin activity in high renin essential hyper-tension. Am J Hypertens 3: 903-905, 1990.
18. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1: 74-76, 1982.
19. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A. 1, 25-Dihydroxyvitamin D down-regulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 277: 38965-38971, 2002.
20. Cowell RM, Russell JW. Nitrosative injury and antioxidant therapy in the management of diabetic neuropathy. J Investig Med 52: 33-44, 2004.
21. Crivello JF. Oxidative stress limits vitamin D metabolism by bovine proximal tubule cells in vitro. Arch Biochem Biophys 262: 471-480, 1988.
22. Chai SY, Zhuo J, Mendelsohn FA. Localization of components of the renin-angiotensin system and site of action of inhibitors. Arzneimittel-forschung 43: 214-221, 1993.
23. Chang JM, Kuo MC, Kuo HT, Hwang SJ, Tsai JC, Chen HC, Lai YH. 1α, 25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. J Lab Clin Med 143: 14-22, 2004.
24. Chansel D, Ardaillou R. [Active metabolites derived from angiotensin II]. Nephrologie 19: 427-432, 1998.
25. de Cavanagh EM, Ferder L, Toblli JE, Piotrkowski B, Stella I, Fraga CG, Inserra F. Renal mitochondrial impairment is attenuated by AT1 blockade in experimental type 1 diabetes. Am J Physiol Heart Circ Physiol 294: H456-H465, 2008.
26. de Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol 296: H550-H558, 2009.
27. de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc Res 89: 31-40, 2011.
28. de Cavanagh EM, Inserra F, Ferder M, Ferder L. From mitochondria to disease: role of the renin-angiotensin system. Am J Nephrol 27: 545-553, 2007.
29. Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, Wong KE, Kong J, Li YC. 1, 25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway. Am J Physiol Renal Physiol 296: F1212-F1218, 2009.
30. Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond) 100: 481-492, 2001.
31. Dirks-Naylor AJ, Lennon-Edwards S. The effects of vitamin D on skeletal muscle function and cellular signaling. J Steroid Biochem Mol Biol 125: 159-168, 2011.
32. Ebert R, Schutze N, Adamski J, Jakob F. Vitamin D signaling is modulated on multiple levels in health and disease. Mol Cell Endocrinol 248: 149-159, 2006.
33. Elangovan V, Shohami E, Gati I, Kohen R. Increased hepatic lipid soluble antioxidant capacity compared with other organs of streptozoto-cin-induced diabetic rats: a cyclic voltammetry study. Free Radic Res 32: 125-134, 2000.
34. Ferder L, Inserra F, Martinez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 8: 191-198, 2006.
35. Ferder LF, Inserra F, Basso N. Advances in our understanding of aging: role of the renin-angiotensin system. Curr Opin Pharmacol 2: 189-194, 2002.
36. Fiscella K, Franks P. Vitamin D, race, and cardiovascular mortality: findings from a national US sample. Ann Fam Med 8: 11-18, 2010.
37. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74: 1394-1402, 2008.
38. Fryer RM, Rakestraw PA, Nakane M, Dixon D, Banfor PN, Koch KA, Wu-Wong JR, Reinhart GA. Differential inhibition of rennin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 106: p76-p81, 2007.
39. Garcia IM, Altamirano L, Mazzei L, Fornes M, Molina MN, Ferder L, Manucha W. Role of mitochondria in paricalcitol-mediated cytopro-tection during obstructive nephropathy. Am J Physiol Renal Physiol 302: F1595-F1605, 2012.
40. Geldmeyer-Hilt K, Heine G, Hartmann B, Baumgrass R, Radbruch A, Worm M. 1, 25-Dihydroxyvitamin D3 impairs NF-κB activation in human naive B cells. Biochem Biophys Res Commun 407: 699-702, 2011.
41. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 169: 626-632, 2009.
42. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1, 25-Dihydroxyvitamin D3 works as anti-inflammatory. Diabetes Res Clin Pract 77: 47-57, 2007.
43. Gonzalez-Pardo V, Boland R, de Boland AR. Vitamin D receptor levels and binding are reduced in aged rat intestinal subcellular fractions. Biogerontology 9: 109-118, 2008.
44. Goodfriend TL. Angiotensin receptors: history and mysteries. Am J Hypertens 13: 442-449, 2000.
45. Gorin Y, Ricono JM, Wagner B, Kim NH, Bhandari B, Choudhury GG, Abboud HE. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 381: 231-239, 2004.
46. Griendling KK, Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 91: 21-27, 2000.
47. Groban L, Pailes NA, Bennett CD, Carter CS, Chappell MC, Kitzman DW, Sonntag WE. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci 61: 28-35, 2006.
48. Gutierrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int 22: 1745-1753, 2011.
49. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 70: 1067-1116, 1990.
50. Haskins K, Kench J, Powers K, Bradley B, Pugazhenthi S, Reusch J, McDuffie M. Role for oxidative stress in the regeneration of islet beta cells? J Investig Med 52: 45-49, 2004.
51. Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf) 76: 315-325, 2012.
52. Ho E, Bray TM. Antioxidants, NFκB activation, diabetogenesis. Proc Soc Exp Biol Med 222: 205-213, 1999.
53. Hoeck AD, Pall ML. Will vitamin D supplementation ameliorate diseases characterized by chronic inflammation and fatigue? Med Hypotheses 76: 208-213, 2011.
54. Holick MF. Environmental factors that influence the cutaneous production of vitamin D. Am J Clin Nutr 61: 638S-645S, 1995.
55. Holick MF. Phylogenetic and evolutionary aspects of vitamin D from phytoplankton to humans. In: Vertebrate Endocrinology: Fundamentals and Biomedical Implications, edited by Pang PS. Orlando, FL: Aca-demic, 1989, p. 7-43.
56. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80: 1678S-1688S, 2004.
57. Holick MF. Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.
58. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem 88: 296-307, 2003.
59. Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 12: 4-18, 2011.
60. Holick MF. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes Obes 9: 87-98, 2002.
61. Hsieh JC, Sisk JM, Jurutka PW, Haussler CA, Slater SA, Haussler MR, Thompson CC. Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling. J Biol Chem 278: 38665-38674, 2003.
62. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW. The vitamin D receptor is present in caveolae-enriched plasma mem-branes and binds 1?, 25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol 18: 2660-2671, 2004.
63. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 32: 296-304, 2010.
64. Ikura Y, Ohsawa M, Shirai N, Sugama Y, Fukushima H, Suekane T, Hirayama M, Ehara S, Naruko T, Ueda M. Expression of angiotensin II type 1 receptor in human cirrhotic livers: its relation to fibrosis and portal hypertension. Hepatol Res 32: 107-116, 2005.
65. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y. α-Klotho as a regulator of calcium homeostasis. Science 316: 1615-1618, 2007.
66. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 21: 295-302, 2011.
67. Ishizaka N, Mitani H, Nagai R. [Angiotensin II regulates klotho gene expression]. Nippon Rinsho 60: 1935-1939, 2002.
68. Jensen LP, Ras G, Boes EG. Hypercalcaemia in pregnancy: a case report. S Afr Med J 57: 712-713, 1980.
69. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the Third National Health and Nutrition Examination Survey. Am J Clin Nutr 87: 136-141, 2008.
70. Kaneto H, Kajimoto Y, Fujitani Y, Matsuoka T, Sakamoto K, Matsuhisa M, Yamasaki Y, Hori M. Oxidative stress induces p21 expression in pancreatic islet cells: possible implication in beta-cell dysfunction. Diabetologia 42: 1093-1097, 1999.
71. Kang YM, Ma Y, Elks C, Zheng JP, Yang ZM, Francis J. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-κB. Cardiovasc Res 79: 671-678, 2008.
72. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, Suzuki T, Maeta H, Abe Y. Role of NAD(P)H oxidase-and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 45: 860-866, 2005.
73. Kimura Y, Kawamura M, Owada M, Oshima T, Murooka M, Fujiwara T, Hiramori K. Effectiveness of 1, 25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathy-roidism patient with high renin activity. Intern Med 38: 31-35, 1999.
74. Koeffler HP, Amatruda T, Ikekawa N, Kobayashi Y, DeLuca HF. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1, 25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res 44: 5624-5628, 1984.
75. Kong J, Li YC. Effect of ANG II type I receptor antagonist and ACE inhibitor on vitamin D receptor-null mice. Am J Physiol Regul Integr Comp Physiol 285: R255-R261, 2003.
76. Kong J, Qiao G, Zhang Z, Liu SQ, Li YC. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression indepen-dent of parathyroid hormone and calcium. Kidney Int 74: 1577-1581, 2008.
77. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 352: 709-710, 1998.
78. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of cal-citriol and blood pressure in normotensive men. Hypertension 30: 1289-1294, 1997.
79. Kuro-o M. Klotho. Pflügers Arch 459: 333-343, 2010.
80. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997.
81. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M. Suppression of aging in mice by the hormone klotho. Science 309: 1829-1833, 2005.
82. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114: 323-334, 2003.
83. Lanske B, Razzaque MS. Vitamin D and aging: old concepts and new insights. J Nutr Biochem 18: 771-777, 2007.
84. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 116: 61-69, 2003.
85. Levi M. Nuclear receptors in renal disease. Biochim Biophys Acta 1812: 1061-1067, 2011.
86. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8: 1235-1242, 2002.
87. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 88: 327-331, 2003.
88. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1, 25-Dihydroxyvi-tamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002.
89. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90: 387-392, 2004.
90. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8: 894-901, 1995.
91. Lind L, Wengle B, Wide L, Ljunghall S. Reduction of blood pressure during long-term treatment with active vitamin D (α-calcidol) is dependent on plasma renin activity and calcium status. A double-blind, place-bo-controlled study. Am J Hypertens 2: 20-25, 1989.
92. Lips P. Vitamin D physiology. Prog Biophys Mol Biol 92: 4-8, 2006.
93. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Tran-scriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10: 142-153, 1996.
94. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773, 2006.
95. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30: 771-777, 2002.
96. Manucha W, Oliveros L, Carrizo L, Seltzer A, Valles P. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney Int 65: 2091-2107, 2004.
97. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardio-vascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Exam-ination Survey. Arch Intern Med 167: 1159-1165, 2007.
98. Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, Jones AF, Barnett AH. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27: 484-490, 1997.
99. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 11: 7-12, 2008.
100. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, Nakamura Y, Sato M, Nangaku M, Hirata Y, Nagai R. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39: 838-843, 2002.
101. Mitsuhashi T, Morris RC Jr, Ives HE. 1, 25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 87: 1889-1895, 1991.
102. Mogi M, Iwai M, Horiuchi M. New insights into the regulation of angiotensin receptors. Curr Opin Nephrol Hypertens 18: 138-143, 2009.
103. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-E65, 2002.
104. Muller DN, Kleinewietfeld M, Kvakan H. Vitamin D review. J Renin Angiotensin Aldosterone Syst 12: 125-128, 2011.
105. Muller DN, Kvakan H, Luft FC. Immune-related effects in hyperten-sion and target-organ damage. Curr Opin Nephrol Hypertens 20: 113-117, 2011.
106. Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW. Identification of a specific binding protein for 1α, 25-dihydroxyvi-tamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem 269: 23750-23756, 1994.
107. Nemerovski CW, Dorsch MP, Simpson RU, Bone HG, Aaronson KD, Bleske BE. Vitamin D and cardiovascular disease. Pharmacotherapy 29: 691-708, 2009.
108. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002.
109. Nishimura H. Angiotensin receptors-evolutionary overview and per-spectives. Comp Biochem Physiol A Mol Integr Physiol 128: 11-30, 2001.
110. O'Kelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 109: 1091-1099, 2002.
111. Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, Proctor BM, Petty M, Chen Z, Schechtman KB, Bernal-Mizrachi L, Bernal-Mizrachi C. 1, 25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabe-tes mellitus. Circulation 120: 687-698, 2009.
112. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49: 69-75, 2007.
113. Ooi JH, Chen J, Cantorna MT. Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors? Mol Aspects Med 33: 77-82, 2012.
114. Oren Y, Shapira Y, Agmon-Levin N, Kivity S, Zafrir Y, Altman A, Lerner A, Shoenfeld Y. Vitamin D insufficiency in a sunny environ-ment: a demographic and seasonal analysis. Isr Med Assoc J 12: 751-756, 2010.
115. Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW. Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. Gastroenterology 123: 1667-1676, 2002.
116. Pan L, Gross KW. Transcriptional regulation of renin: an update. Hypertension 45: 3-8, 2005.
117. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardio-vasc Res 71: 247-258, 2006.
118. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK. Intravenous calcitriol regresses myocardial hy-pertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33: 73-81, 1999.
119. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angio-tensin systems. Physiol Rev 86: 747-803, 2006.
120. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107: 853-860, 2001.
121. Persson PB, Skalweit A, Mrowka R, Thiele BJ. Control of rennin synthesis. Am J Physiol Regul Integr Comp Physiol 285: R491-R497, 2003.
122. Peterson CA, Heffernan ME. Serum tumor necrosis factor-α concen-trations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm 5: 10, 2008.
123. Pfeifer M, Begerow B, Minne HW, Nachtigall D, Hansen C. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 86: 1633-1637, 2001.
124. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 6: 621-630, 2009.
125. Porsti IH. Expanding targets of vitamin D receptor activation: down-regulation of several RAS components in the kidney. Kidney Int 74: 1371-1373, 2008.
126. Pueyo ME, Arnal JF, Rami J, Michel JB. Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol Cell Physiol 274: C214-C220, 1998.
127. Queisser N, Oteiza PI, Stopper H, Oli RG, Schupp N. Aldosterone induces oxidative stress, oxidative DNA damage and NF-κB activation in kidney tubule cells. Mol Carcinog 50: 123-135, 2011.
128. Quesada JM, Martin-Malo A, Santiago J, Hervas F, Martinez ME, Castillo D, Barrio V, Aljama P. Effect of calcitriol on insulin secretion in uraemia. Nephrol Dial Transplant 5: 1013-1017, 1990.
129. Rema M, Mohan V, Bhaskar A, Shanmugasundaram KR. Does oxidant stress play a role in diabetic retinopathy? Indian J Ophthalmol 43: 17-21, 1995.
130. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
131. Reschly EJ, Bainy AC, Mattos JJ, Hagey LR, Bahary N, Mada SR, Ou J, Venkataramanan R, Krasowski MD. Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol 7: 222, 2007.
132. Resnick LM, Muller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 105: 649-654, 1986.
133. Rincon-Choles H, Kasinath BS, Gorin Y, Abboud HE. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl: 8-11, 2002.
134. Ritthaler T, Scholz H, Ackermann M, Riegger G, Kurtz A, Kramer BK. Effects of endothelins on renin secretion from isolated mouse renal juxtaglomerular cells. Am J Physiol Renal Fluid Electrolyte Physiol 268: F39-F45, 1995.
135. Robey RB, Crane-Godreau MA. "Does sunscreen promote hyperten-sion?" and other questions. Novel interactions between vitamin D and the renin-angiotensin axis. Focus on "The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system." Am J Physiol Cell Physiol (April 10, 2013). doi:10.1152/ajpcell.00090.2013.
136. Rostand SG. Vitamin D, blood pressure, and African Americans: toward a unifying hypothesis. Clin J Am Soc Nephrol 5: 1697-1703, 2010.
137. Salzet M, Deloffre L, Breton C, Vieau D, Schoofs L. The angiotensin system elements in invertebrates. Brain Res Brain Res Rev 36: 35-45, 2001.
138. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Exami-nation Survey. Am J Hypertens 20: 713-719, 2007.
139. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, pla-cebo-controlled trial. Am J Clin Nutr 83: 754-759, 2006.
140. Serrano GL, Ritchie B, Hoffman D, Ferder L. A new concept for an old system: the anti-inflammatory paradigm of the renin-angiotensin system. Med Hypotheses 72: 584-588, 2009.
141. Shahbazi M, Jeddi-Tehrani M, Zareie M, Salek-Moghaddam A, Akhondi MM, Bahmanpoor M, Sadeghi MR, Zarnani AH. Expression profiling of vitamin D receptor in placenta, decidua and ovary of pregnant mice. Placenta 32: 657-664, 2011.
142. Shintani S, Terzic J, Sato A, Saraga-Babic M, O'HUigin C, Tichy H, Klein J. Do lampreys have lymphocytes? The Spi evidence. Proc Natl Acad Sci USA 97: 7417-7422, 2000.
143. Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescar-mona G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLos One 5: e8670.
144. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103: 521-524, 2007.
145. Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, Jaccard N, Knoll E, Stern N. 25-Hydroxyvitamin D3-1?-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111: 1666-1671, 2005.
146. +T cells. J Immunol 168: 1181-1189, 2002.
147. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25: 320-325, 2008.
148. Swami S, Krishnan AV, Feldman D. Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol 347: 61-69, 2011.
149. Takiishi T, Gysemans C, Bouillon R, Mathieu C. Vitamin D and diabetes. Endocrinol Metab Clin North Am 39: 419-446, 2010.
150. Tan X, He W, Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int 76: 1248-1257, 2009.
151. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17: 3382-3393, 2006.
152. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-κB signal-ing. J Am Soc Nephrol 19: 1741-1752, 2008.
153. Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, Kadowaki D, Maruyama T, Otagiri M, Fukagawa M. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 15: 161-168, 2011.
154. Tang R, Zhou Q, Shu J, Tang T, Ao X, Peng W, Zhang Y. [Effect of Cordyceps sinensis extract on klotho expression and apoptosis in renal tubular epithelial cells induced by angiotensin II]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34: 300-307, 2009.
155. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insuffi-ciency among free-living healthy young adults. Am J Med 112: 659-662, 2002.
156. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581, 2006.
157. Thompson MM, Oyama TT, Kelly FJ, Kennefick TM, Anderson S. Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol 279: R1787-R1794, 2000.
158. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97: 22-28, 1996.
159. Toda N, Ayajiki K, Okamura T. Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev 59: 54-87, 2007.
160. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, Marz W. Independent association between 1, 25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwig-shafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta 411: 1354-1360, 2010.
161. Touyz RM. Activated oxygen metabolites: do they really play a role in angiotensin II-regulated vascular tone? J Hypertens 21: 2235-2238, 2003.
162. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 14: 125-131, 2005.
163. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep 2: 98-105, 2000.
164. Touyz RM. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther 1: 91-106, 2003.
165. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17: 2393-2403, 2003.
166. Tuohimaa P. Vitamin D and aging. J Steroid Biochem Mol Biol 114: 78-84, 2009.
167. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 98: 1966-1970, 1996.
168. Verhave G, Siegert CE. Role of vitamin D in cardiovascular disease. Neth J Med 68: 113-118, 2010.
169. Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, Vatner SF, Lakatta EG. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 41: 1308-1316, 2003.
170. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511, 2008.
171. Wei HS, Li DG, Lu HM, Zhan YT, Wang ZR, Huang X, Zhang J, Cheng JL, Xu QF. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4. World J Gastroenterol 6: 540-545, 2000.
172. Weinreich T, Landolt M, Booy C, Wuthrich R, Binswanger U. 1, 25-Dihydroxyvitamin D3 stimulates transforming growth factor-β1 synthesis by mouse renal proximal tubular cells. Kidney Blood Press Res 22: 99-105, 1999.
173. Whitfield GK, Dang HT, Schluter SF, Bernstein RM, Bunag T, Manzon LA, Hsieh G, Dominguez CE, Youson JH, Haussler MR, Marchalonis JJ. Cloning of a functional vitamin D receptor from the lamprey (Petromyzon marinus), an ancient vertebrate lacking a calcified skeleton and teeth. Endocrinology 144: 2704-2716, 2003.
174. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin sys-tems. Am J Physiol Endocrinol Metab 288: E125-E132, 2005.
175. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1, 25-Dihydroxyvitamin D3 suppresses rennin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282: 29821-29830, 2007.
176. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M. Synthesis of 1, 25-dihydroxyvitamin D3 by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13: 621-629, 2002.
177. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 21: 966-973, 2010.
178. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC. Renoprotective role of the vitamin D receptor in diabetic nephrop-athy. Kidney Int 73: 163-171, 2008.
179. Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, Kong J, Li YC. 1, 25-Dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 72: 193-201, 2007.
180. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105: 15896-15901, 2008.
181. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angio-tensin system in 1α-hydroxylase knockout mice. Kidney Int 74: 170-179, 2008.
182. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 92: 39-48, 2006.